What is he best known for?
The fields of study he is best known for:
Cancer research, Rhabdomyosarcoma, Pharmacology, Cell biology and PI3K/AKT/mTOR pathway are his primary areas of study.
Peter J. Houghton interconnects Growth factor receptor, Methyltransferase, Immunology and Protein kinase A in the investigation of issues within Cancer research.
His Rhabdomyosarcoma research is multidisciplinary, incorporating elements of Internal medicine, Chemotherapy and Neuroblastoma.
His Pharmacology research is multidisciplinary, incorporating perspectives in Camptothecin, Irinotecan, Transplantation and In vivo.
As a part of the same scientific study, he usually deals with the In vivo, concentrating on In vitro and frequently concerns with Osteosarcoma and Distribution.
His research in Cell biology intersects with topics in Cell cycle, Transcription factor and Cell culture.
His most cited work include:
- The tor pathway: a target for cancer therapy (1163 citations)
- Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin (842 citations)
- mTOR and cancer therapy. (404 citations)
What are the main themes of his work throughout his whole career to date?
Peter J. Houghton focuses on Cancer research, In vivo, Pharmacology, Rhabdomyosarcoma and Internal medicine.
Within one scientific family, Peter J. Houghton focuses on topics pertaining to PI3K/AKT/mTOR pathway under Cancer research, and may sometimes address concerns connected to Cell growth and Phosphorylation.
Peter J. Houghton focuses mostly in the field of In vivo, narrowing it down to topics relating to Cell culture and, in certain cases, Molecular biology.
Peter J. Houghton works mostly in the field of Pharmacology, limiting it down to topics relating to Irinotecan and, in certain cases, Camptothecin, as a part of the same area of interest.
His research in Rhabdomyosarcoma tackles topics such as Vincristine which are related to areas like Melphalan.
His Internal medicine research incorporates themes from Endocrinology and Oncology.
He most often published in these fields:
- Cancer research (42.28%)
- In vivo (27.18%)
- Pharmacology (24.50%)
What were the highlights of his more recent work (between 2014-2021)?
- Cancer research (42.28%)
- Cancer (18.46%)
- In vivo (27.18%)
In recent papers he was focusing on the following fields of study:
His main research concerns Cancer research, Cancer, In vivo, Internal medicine and Sarcoma.
Particularly relevant to Osteosarcoma is his body of work in Cancer research.
His In vivo study also includes
- Vincristine most often made with reference to Pharmacology,
- IC50 which intersects with area such as Distribution.
His work in the fields of Internal medicine, such as Leukemia, Toxicity and Novel agents, overlaps with other areas such as Preclinical testing.
When carried out as part of a general Sarcoma research project, his work on Rhabdomyosarcoma is frequently linked to work in Eribulin, therefore connecting diverse disciplines of study.
While the research belongs to areas of Cell culture, he spends his time largely on the problem of Cell growth, intersecting his research to questions surrounding PI3K/AKT/mTOR pathway and Transcription factor.
Between 2014 and 2021, his most popular works were:
- Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling (95 citations)
- Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia (79 citations)
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program (75 citations)
In his most recent research, the most cited papers focused on:
Peter J. Houghton mainly focuses on Cancer research, In vivo, Internal medicine, Pharmacology and Sarcoma.
His work carried out in the field of Cancer research brings together such families of science as Cancer and Leukemia, Immunology.
His In vivo research integrates issues from IC50, In vitro, Vincristine, Downregulation and upregulation and Wilms' tumor.
In his study, Tumor xenograft, Potency and Docetaxel is strongly linked to Oncology, which falls under the umbrella field of Internal medicine.
His research in Pharmacology is mostly focused on Pharmacokinetics.
The Rhabdomyosarcoma research Peter J. Houghton does as part of his general Sarcoma study is frequently linked to other disciplines of science, such as Eribulin, therefore creating a link between diverse domains of science.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
